TABLE 2.
Descriptive statistics for included participants at 3 months (end‐of‐treatment)
| Remission (n = 63) n (%) | Relapse (n = 26) n (%) | Total (n = 89) n (%) | Χ 2 | df | p | |
|---|---|---|---|---|---|---|
| Age M (SD) | 37.02 (13.79) | 29.54 (10.88) | 34.83 (13.39) | 2.464 d | 87 | 0.016 |
| Gender | ||||||
| Male | 17 (27) | 3 (11.5) | 20 (22.5) | 2.520 | 1 | 0.112 |
| Female | 46 (73) | 23 (88.5) | 69 (77.5) | |||
| Ethnicity a | ||||||
| White | 53 (85.5) | 19 (73.1) | 72 (81.8) | 1.896 | 1 | 0.169 |
| Other | 9 (14.5) | 7 (26.9) | 16 (18.2) | |||
| Long‐term condition | ||||||
| Yes | 10 (15.9) | 6 (24) | 16 (18.2) | 0.795 | 1 | 0.373 |
| No | 53 (84.1) | 19 (76) | 72 (81.8) | |||
| Employment status b | ||||||
| Employed | 47 (79.7) | 18 (69.2) | 65 (76.5) | 1.091 | 1 | 0.296 |
| Unemployed/student | 12 (20.3) | 8 (30.8) | 20 (23.5) | |||
| Medication c | ||||||
| Taking | 16 (27.6) | 7 (26.9) | 23 (27.4) | 0.004 | 1 | 0.950 |
| Not taking | 42 (72.4) | 19 (73.1) | 61 (72.6) | |||
| MINI diagnosis a | ||||||
| Yes | 15 (24.2) | 7 (26.9) | 22 (25) | 0.073 | 1 | 0.787 |
| No | 47 (75.8) | 19 (73.1) | 66 (75) | |||
| PHQ‐9 residual symptoms e | ||||||
| Yes | 24 (38.1) | 13 (50) | 37 (41.6) | 1.074 | 1 | 0.300 |
| No | 39 (61.9) | 13 (50) | 52 (58.4) | |||
| GAD‐7 residual symptoms | ||||||
| Yes | 20 (31.7) | 10 (38.5) | 30 (33.7) | 0.371 | 1 | 0.542 |
| No | 43 (68.3) | 16 (61.5) | 59 (66.3) | |||
a
Total n = 88.
b
Total n = 85.
c
Total n = 84.
d
T test value.
e
Residual symptoms = PHQ‐9 score 5–9; GAD‐7 score 5–7.